文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

高GOLT1A表达导致甲状腺乳头状癌预后不良。

High GOLT1A expression induces poor prognosis in papillary thyroid carcinoma.

作者信息

Ding Tianjiao, Zhu Yiyu, Zhou Hanjia, Zhang Zihan, Gao Erli

机构信息

Department of General Surgery, The First Affiliated Hospital of Soochow University, 899 Pinghai Street, Suzhou, 215006, Jiangsu, China.

Wenzhou Medical University, Wenzhou, Zhejiang, China.

出版信息

Sci Rep. 2025 Jul 1;15(1):20979. doi: 10.1038/s41598-025-05747-x.


DOI:10.1038/s41598-025-05747-x
PMID:40593102
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12217172/
Abstract

This study aims to investigate the clinical relevance of GOLT1A in papillary thyroid carcinoma (PTC) and evaluate its significance in prognosis of PTC. In this study, 527 data downloaded from the TCGA database and 280 data downloaded from the GTEx database were used for differential gene expression analysis. Univariate and multivariate statistical analyses were performed on the data of 499 PTC patients from the TCGA database and the data of 305 PTC patients subjected to fine-needle aspiration biopsy (FNAB) from the Department of General Surgery of the First Affiliated Hospital of Soochow University and the First Affiliated Hospital of Wenzhou Medical University. In the gene expression of 527 normal tissues and thyroid carcinoma tissues data from the TCGA database and 280 normal tissues from the GTEx database, the expression of GOLT1A was significantly higher in thyroid carcinoma tissues than in normal thyroid tissues (P < 0.001), validated by GEO databases (P < 0.001) and immunohistochemical (IHC) (P < 0.05). Univariate and multivariate analyses of 499 PTC patients and 309 FNAB PTC patients in the TCGA database showed that high expression of GOLT1A was closely related to the poor prognosis of PTC. Specifically, GOLT1A is associated with differentiation risk (P = 0.005), sex (P = 0.006), capsular invasion (P = 0.038) and lateral lymph node metastasis (P < 0.001). In summary, the expression of GOLT1A in thyroid carcinoma tissues was significantly higher than that in normal tissues, and high GOLT1A expression was probably related to the poor prognosis of PTC. GOLT1A is a promising prognostic genetic marker and pathogenic target of PTC.

摘要

本研究旨在探讨GOLT1A在甲状腺乳头状癌(PTC)中的临床相关性,并评估其在PTC预后中的意义。本研究中,从TCGA数据库下载的527条数据和从GTEx数据库下载的280条数据用于差异基因表达分析。对来自TCGA数据库的499例PTC患者的数据以及来自苏州大学附属第一医院和温州医科大学附属第一医院普通外科的305例接受细针穿刺活检(FNAB)的PTC患者的数据进行单因素和多因素统计分析。在来自TCGA数据库的527例正常组织和甲状腺癌组织数据以及来自GTEx数据库的280例正常组织的基因表达中,GOLT1A在甲状腺癌组织中的表达显著高于正常甲状腺组织(P<0.001),经GEO数据库(P<0.001)和免疫组织化学(IHC)验证(P<0.05)。对TCGA数据库中的499例PTC患者和309例FNAB PTC患者进行单因素和多因素分析表明,GOLT1A的高表达与PTC的不良预后密切相关。具体而言,GOLT1A与分化风险(P=0.005)、性别(P=0.006)、包膜侵犯(P=0.038)和侧方淋巴结转移(P<0.001)相关。综上所述,GOLT1A在甲状腺癌组织中的表达显著高于正常组织,GOLT1A的高表达可能与PTC的不良预后有关。GOLT1A是一种有前景的PTC预后遗传标志物和致病靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fad/12217172/e32298e13248/41598_2025_5747_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fad/12217172/d91851ccb686/41598_2025_5747_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fad/12217172/0684cd5e397c/41598_2025_5747_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fad/12217172/8eadc2022665/41598_2025_5747_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fad/12217172/e32298e13248/41598_2025_5747_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fad/12217172/d91851ccb686/41598_2025_5747_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fad/12217172/0684cd5e397c/41598_2025_5747_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fad/12217172/8eadc2022665/41598_2025_5747_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5fad/12217172/e32298e13248/41598_2025_5747_Fig4_HTML.jpg

相似文献

[1]
High GOLT1A expression induces poor prognosis in papillary thyroid carcinoma.

Sci Rep. 2025-7-1

[2]
Analysis of histological features and recurrence risk assessment of papillary thyroid carcinoma according to presurgery FNAC category.

Updates Surg. 2025-2-26

[3]
Expression and clinical significance of AUF1 and HIF-1α in papillary thyroid carcinoma.

World J Surg Oncol. 2025-7-1

[4]
Can mutation abundance assess the biological behavior of BRAF-positive papillary thyroid carcinoma?

J Transl Med. 2025-7-1

[5]
BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.

Medicine (Baltimore). 2012-9

[6]
Multigene Detection Analysis of Multifocal Papillary Thyroid Carcinoma.

Clin Endocrinol (Oxf). 2025-8

[7]
Clinical impact of BRAF mutation on the diagnosis and prognosis of papillary thyroid carcinoma: a systematic review and meta-analysis.

Eur J Clin Invest. 2016-2

[8]
EIF4A3-Induced Circ_0092278 Enhances Papillary Thyroid Cancer Cell Malignancy by the PI3K/Akt/mTOR Signaling Pathway.

J Microbiol Biotechnol. 2025-6-19

[9]
MicroRNA-101 Targets CXCL12-Mediated Akt and Snail Signaling Pathways to Inhibit Cellular Proliferation and Invasion in Papillary Thyroid Carcinoma.

Oncol Res. 2019-3-4

[10]
Establishment of novel prognostic groups for papillary thyroid carcinoma using a modified risk classification based on tumor extension in the guidelines of the Japan Association of Endocrine Surgery.

Endocr J. 2025-6-2

本文引用的文献

[1]
Trends and projections of the global burden of thyroid cancer from 1990 to 2030.

J Glob Health. 2024-5-17

[2]
Natural killer cell subsets and their functional molecules in peripheral blood of the patients with breast cancer.

Immun Inflamm Dis. 2024-4

[3]
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA Cancer J Clin. 2024

[4]
Blood leukocytes as a non-invasive diagnostic tool for thyroid nodules: a prospective cohort study.

BMC Med. 2024-4-2

[5]
Thyroid Cancer: A Review.

JAMA. 2024-2-6

[6]
Cancer statistics, 2024.

CA Cancer J Clin. 2024

[7]
Does the presence of capsule influence prognosis in poorly differentiated thyroid carcinoma?

Hum Pathol. 2023-6

[8]
Cell-free DNA methylation biomarker for the diagnosis of papillary thyroid carcinoma.

EBioMedicine. 2023-4

[9]
Circ0005654 as a new biomarker of thyroid cancer interacting with SP1 to influence the prognosis: A case-control study.

Medicine (Baltimore). 2023-2-10

[10]
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2022-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索